Cue Health Becomes First Company to Receive FDA De Novo Authorization COVID-19 Home Use Test

Cue Health Inc HLTH became the first company to receive De Novo authorization from the FDA for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use.

The de novo is a device classification process that allows the FDA to classify new devices that are not equivalent to the existing Class I or II devices.

Originally made available to consumers without a prescription through a 2021 FDA Emergency Use Authorization (EUA), Cue's COVID-19 test delivers results in just 20 minutes to connected mobile smart devices. 

With a demonstrated overall accuracy of 98%, the test detects all known COVID-19 variants of concern and integrates into Cue Care, the company's test-to-treatment service.

The project has been funded in whole or in part with federal funds awarded by the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, beginning in June 2018.

Last month, Cue Health submitted a De Novo to the FDA for full clearance of the Cue RSV Molecular Test for at-home and point-of-care use

There are currently no respiratory syncytial virus (RSV) tests for home use. Pending FDA clearance, Cue's test would provide the public, for the first time, an at-home molecular RSV test to use on people of all ages.

Price Action: HLTH shares are down 3.94% at $0.57 during the premarket session on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareFDAGeneralBriefsCOVID-19 CoronavirusHealth CareHealth Care Technology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!